Affiliations Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands, Department of Neurology & Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands
Auto-generated profile, based on publicly available information
Anouk M de Jong
Affiliations Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands, Department of Neurology & Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands
Background: Recurrence of high-grade glioma after primary treatment is inevitable. New contrast-enhancing lesions on follow-up MRI may indicate tumor progression, treatment-associated changes (TAC), or both. A repeated surgical procedure, either biopsy or resection, provides diagnostic clarity and therapeutic benefit, but carries risks. In the patient-specific decision to operate, current literature offers limited guidance on which patients may benefit. This study aimed to describe functional outcomes after repeat surgery of previously irradiated glioma, and to identify predictors of functional deterioration. Methods: Single-center retrospective cohort study. Adults with diffuse glioma who underwent first-line radiotherapy and subsequent repeat surgery (biopsy or resection) for suspected high-grade radiological progression were included. Lesions were histologically classified as progression, TAC, or both. The primary endpoint was functional outcome 30 days postoperatively, expressed as decline of Karnofsky Performance Status (KPS). Logistic regression identified predictors of KPS decline. Survival was assessed with Kaplan-Meier and Cox regression. Results: Of 166 patients, 37 (22.3%) experienced a KPS deterioration, 127 (76.5%) remained stable, and 2 (1.2%) improved. Rates of functional deterioration were similar after biopsies and resections. Preoperative steroid usage (odds ratio = 2.73, 95% confidence interval = 1.09-6.79, P = .031) was associated with KPS deterioration. Histological diagnosis was not associated with functional outcome (χ2, P = .361). Patients with deterioration had shorter median survival (4 vs 11 months, P < .001). Conclusions: In this cohort, 22.3% of patients experienced functional decline 30 days after a repeat surgery (biopsy or resection). Preoperative steroid usage predicted deterioration. These findings may provide clinical guidance in identifying which patients will benefit from repeat surgery.
Background: Reirradiation is a widely accepted option for second-line treatment in patients with recurrent glioma. However, no standard radiation regimen has been defined. Hypofractionation is aimed at reducing patients’ burden while maintaining the survival benefit, but may increase the risk of radionecrosis. The primary objective of this study is to determine if reirradiation in just 4 fractions is non-inferior to 10 fractions, regarding survival after reirradiation. Methods: RISING trial A was an open label, randomized, non-inferiority, phase III trial with 1:1 allocation for 130 patients among all participating centers but failed to recruit according to planning. RISING trial B will be a phase II, multi-center, clinical trial with a historic control group. The experimental group receives 4 stereotactic fractions. The historic control group has received 10 fractions (standard-of-care) with a biologically equivalent dose on surrounding brain tissue. The primary endpoint is overall survival after reirradiation. The key secondary endpoint is progression-free survival. Other secondary endpoints are recurrence patterns, toxicity (specifically clinically relevant radionecrosis) and anti-edema treatment. We will collect and report on Health-Related Quality of Life (HRQoL) data in the experimental arm. Discussion: We expect to demonstrate the non-inferiority and safety of a 4-fraction hypofractionation schedule for reirradiation of gliomas. This schedule may then become a standard-of-care option with minimal burden for patients with recurrent glioma, and limited use of scarce healthcare resources. Trial registration: Registered at Netherlands Trial Register (NTR), Trial ID: NL72766.041.20, registered at 07-04-2020, https://www.onderzoekmetmensen.nl/en/trial/52643